Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resatorvid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 known ✓ | O00206 | 9/20 | 1.00 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resatorvid SCHEMBL871572 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL1821271 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL872197 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL30113148 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871253 | 0.97 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871685 | 0.94 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944442 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944682 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944518 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944446 | 0.90 | TLR4 (0.85) | TLR4MRGPRX1TSPOHRH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022112641-A1 | METHOD FOR DETERMINING THE EVOLUTION OF ACUTE BRAIN DAMAGE AND PHARMACEUTICAL COMPOSITION FOR TREATING SAME | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) | 2022-06-02 | — | — | WO | claimed |
| EP-4110368-B1 | TREATMENT OF LIVER FAILURE | HEPYX LTD (GB) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024261477-A1 | COMBINATION OF TLR4 ANTAGONIST, ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | disclosed |
| EP-3406242-B1 | TLR44 ANTAGONIST FOR USE IN THE TREATMENT OF INCREASED AMMONIA PLASMA LEVELS | YAQRIT LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20230136299-A1 | TREATMENT OF LIVER FAILURE | HEPYX LIMITED (GB) | 2023-05-04 | — | — | US | disclosed |
| US-11598774-B2 | Methods of diagnosis and treatment of Alzheimer's Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4096647-A1 | TREATING ACUTE LIVER DISEASE WITH TLR-MIK INHIBITORS | Yeda Research and Development Co. Ltd (IL) | 2022-12-07 | — | — | EP | disclosed |
| US-20220362329-A1 | TREATING ACUTE LIVER DISEASE WITH TLR-MIK INIHIBITORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-11-17 | — | — | US | disclosed |
| WO-2022112641-A1 | METHOD FOR DETERMINING THE EVOLUTION OF ACUTE BRAIN DAMAGE AND PHARMACEUTICAL COMPOSITION FOR TREATING SAME | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) | 2022-06-02 | — | — | WO | disclosed |